

1 **Title: Prevalence of Common Respiratory Viruses in Children: Insights from Post-**
2 **Pandemic Surveillance**

3 Constance Adu-Gyamfi^{1,2}, Jesse Addo Asamoah^{1,3}, James Opoku Frimpong^{2,6}, Richard Larbi⁶,
4 Richard Owusu Ansah⁶, Sherihane Naa Ayeley Aryeetey¹, Richmond Gorman¹, Henry
5 Kyeremateng Acheampong¹, Emmanuella Nyarko-Afriyie¹, Manuella Hayford¹, Henrietta
6 Dede Tetteh¹, Kwadwo Boampong³, Veronica Barnor^{5,7}, Peter K. Brenya⁸, Frederick Ayensu⁸,
7 NK. Ayisi-Boateng^{1,5,9}, Philip El-Duah^{1,10}, Christian Drosten^{1,10}, Richard Odame Phillips^{1,5},
8 Augustina Angelina Sylverken^{1,3*}, Michael Owusu^{1,4,6*}

9 adugyamfi.constance.cag@gmail.com

10 jesseasamoah1@gmail.com

11 opokufrimpongjames90@gmail.com

12 richardlarbi003@gmail.com

13 oarichard67@gmail.com

14 asherihanne@gmail.com

15 Richgormann3@gmail.com

16 henri9557@gmail.com

17 afriyieemanuella1806@gmail.com

18 manuellahayford66@gmail.com

19 henrietta.d.tetteh@gmail.com

20 kwadwo.boampong@knust.edu.gh

21 veronicabarnor@gmail.com

22 peter.brenya@hxcmc.org

23 freysuinitiative@gmail.com

24 ayisi31@gmail.com

25 philip.el-duah@charite.de

26 christian.drosten@charite.de

27 phillips@kccr.de

28 auguean@yahoo.com

29 michaelowusu80@gmail.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 **Affiliations**

31 ¹Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana

32 ²Department of Clinical Microbiology, College of Health Sciences, Kwame Nkrumah
33 University of Science and Technology (KNUST), Kumasi, Ghana

34 ³Department of Theoretical and Applied Biology, College of Science, Kwame Nkrumah
35 University of Science and Technology (KNUST), Kumasi, Ghana

36 ⁴Department of Medical Diagnostics, College of Health Sciences, Kwame Nkrumah University
37 of Science and Technology (KNUST), Kumasi, Ghana

38 ⁵School of Medicine and Dentistry, College of Health Sciences, Kwame Nkrumah University
39 of Science and Technology (KNUST), Kumasi, Ghana

40 ⁶Genomics and Infectious Diseases Laboratory, Faculty of Allied Health Sciences (FAHS),
41 Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana

42 ⁷Asokwa Children's Hospital (ACH), Kumasi, Ghana

43 ⁸HopeXchange Medical Centre, Kumasi Ghana

44 ⁹University Health Services, Kwame Nkrumah University of Science and Technology
45 (KNUST), Kumasi, Ghana

46 ¹⁰Institute of Virology - Charité – Universitätsmedizin Berlin, Germany

47 **First authors**

48 1. Constance Adu-Gyamfi

49 Department of Clinical Microbiology, College of Health Sciences, Kwame Nkrumah
50 University of Science and Technology (KNUST), Kumasi

51 2. Jesse Addo Asamoah

52 Department of Theoretical and Applied Biology, College of Science, Kwame Nkrumah
53 University of Science and Technology (KNUST), Kumasi – Ghana

54 **Corresponding authors**

55 *Corresponding authors:

56 1. Dr Michael Owusu

57 Department of Medical Diagnostics, College of Health Sciences, Kwame Nkrumah
58 University of Science and Technology (KNUST), Kumasi

59 michaelowusu80@gmail.com, Tel: +233 243 409 559

60 2. Dr Augustina Angelina Sylverken

61 Department of Theoretical and Applied Biology, Kwame Nkrumah University of
62 Science and Technology, Kumasi

63 auguean@yahoo.com, Tel: +233 244 214 625

64

65

66 **Abstract**

67 **Introduction:** The COVID-19 pandemic has significantly affected healthcare systems
68 worldwide, impacting the occurrence and management of respiratory illnesses. This has also
69 influenced respiratory infections' role in childhood mortality. Surveillance of common
70 respiratory viruses in Ghana is limited, making it crucial to assess the prevalence of respiratory
71 viral infections, particularly in children, in the post-pandemic era. This study provides data on
72 the prevalence of respiratory viruses and the associated risk factors in children aged 5 or
73 younger in an urban paediatric hospital setting.

74

75 **Methods:** The study was a cross-sectional study with a convenience sampling method,
76 conducted in four health facilities: Asokwa Children’s Hospital, HopeXchange Medical
77 Centre, University Health Services-KNUST, and Kumasi South Hospital in Kumasi, Ghana,
78 between August 2022 and June 2023. Recruitment was not done in parallel in each hospital.
79 Oropharyngeal swabs were collected from children ≤ 5 years old and screened by RT-qPCR
80 for common respiratory viruses.

81

82 **Results:** Out of the 303 patients enrolled in the study, 165 (54.4%) were male, and 122 (40.3%)
83 were aged from 13 to 36 months. The median age of the patients was 19 months. The most
84 common symptoms reported were cough (87.0%), runny nose (87.0%), and fever (72.0%).
85 Respiratory viruses were detected in 100 (33.0%) of the samples, with 36 (12.0%) testing
86 positive for Human metapneumovirus (HMPV), 27 (8.9%) for RSV, and 20 (6.6%) for Human
87 Adenovirus (HAdV). In 8.0% of the cases, multiple viruses were detected, with HAdV being
88 the most common (75.0%). Children under 6 months (AOR: 4.81, 95% CI: 1.20-24.60) had a
89 higher risk of RSV detection compared to children aged 37 to 60 months. Furthermore, it was
90 found that caregivers with tertiary education had a higher risk of HMPV detection (AOR: 6.91,
91 95% CI: 1.71-47.3).

92

93 **Conclusion:** The study's findings emphasize RSV infection in very young children and the
94 potentially significant role of HMPV in causing respiratory infections among children in
95 Ghana. Active surveillance of common respiratory viruses in healthcare facilities could
96 enhance the management of viral respiratory infection cases in the paediatric population in
97 Ghana.

98

99 **Keywords:** respiratory viruses; children; co-detection; Ghana

100

101 **Introduction**

102 Acute respiratory infections (ARIs) are important causes of illness worldwide, significantly
103 burdening public health. They impact all age groups with a higher child mortality, especially
104 in less developed countries [1]. Children in Sub-Saharan Africa are more than 15 times more
105 likely to die before the age of five owing to ARIs [2]. ARIs in Ghana are part of the top 10
106 causes of hospital admissions and mortality in children under 5 years old [3].

107 Respiratory viruses account for a great percentage of ARIs. Respiratory viruses have been
108 infecting humans for a long time and have evolved, leading to new strains and variants that
109 cause different symptoms. The viruses that have been implicated as the etiological agents of
110 ARIs include respiratory syncytial virus (RSV), influenza virus, human parainfluenza virus
111 (HPIV), human rhinovirus (HRV), human adenovirus (HAdV) and human metapneumovirus
112 (HMPV) [4]. RSV has been reported as the leading cause of severe lower respiratory tract
113 infections with a burden of hospitalizations, especially in children in developing countries [5,
114 6, 7]. Pneumonia due to human metapneumovirus has shown a higher risk of intensive care
115 need in Moroccan children [8]. Influenza virus is also reported as contributing substantially to
116 the burden of hospitalized febrile children in Ghana [9]. The recent coronavirus disease 2019
117 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2
118 (SARS-CoV-2), has further highlighted the role of respiratory viruses in ARIs.

119 The COVID-19 pandemic has profoundly reshaped the landscape of respiratory infections.
120 During the pandemic, respiratory healthcare faced challenges, including disruptions to routine
121 healthcare services, delays in immunization campaigns, and changes in healthcare-seeking
122 patterns [10, 11]. These disruptions significantly influenced the prevalence and patterns of

123 respiratory infections among children [12, 13,14]. As the acute phase of the pandemic caused
124 significant shifts in societal norms, public health initiatives, and healthcare use trends, the
125 transition to the post-pandemic era provides new challenges for healthcare systems and
126 policymakers.

127 Despite the significant burden of respiratory viral infections among children in Ghana, there
128 remains a paucity of comprehensive epidemiological data on circulating viruses with most
129 studies skewed towards RSV and Influenza viruses. This study provides new insight into the
130 changing dynamics of a broad spectrum of respiratory viruses among children in Ghana. The
131 aim was to determine the prevalence of respiratory viruses and identify associated risk factors
132 in children aged 5 or younger in an urban pediatric hospital setting.

133 **Materials and Methods**

134 *Ethical consideration*

135 The protocols used for the study were reviewed and approved by the Committee on Human
136 Research and Publication Ethics (CHRPE), School of Medicine and Dentistry, Kwame
137 Nkrumah University of Science and Technology (KNUST), Ghana (CHRPE/AP/135/22,
138 CHRPE/AP/087/23) and parental consent was obtained from the caregivers/guardians of all the
139 participants by signing or thumb-printing written consent forms.

140

141 *Study design and area*

142 This was a cross-sectional hospital-based study conducted from August 2022 to June 2023 at
143 the following facilities in Kumasi, Ashanti region of Ghana: The University Hospital, KNUST,
144 Asokwa Children’s Hospital, Kumasi South Hospital, and HopeXchange Medical Centre. The
145 KNUST hospital caters for about 150,000 people from over 30 surrounding communities. The

146 Asokwa Children’s Hospital, which solely focuses on the care and management of children
147 younger than 12 years, attends to roughly 6,000 children every month. The Kumasi South
148 Hospital has an outpatient department and a paediatric ward that attends to approximately 4000
149 children monthly. The HopeXchange Medical Centre is a private facility with a paediatric ward
150 that caters to about 1,500 children every month. All children 2 - 60 months who presented to
151 the healthcare facilities with signs and symptoms of acute respiratory infections as defined in
152 the WHO Programme for the Control of Acute Respiratory Infections [15] were enrolled.
153 Participant selection was done without consideration of ethnicity and gender. Patients were
154 excluded if they were over five years old, unable or unwilling to participate, or if they had any
155 chronic lung disease. At enrolment, clinical symptoms and exposure were assessed, and a
156 clinical examination was conducted to measure weight, height, respiratory rate, and peripheral
157 capillary oxygen saturation.

158

159 ***Data and sample collection***

160 According to Obodai *et al* in 2019 [16], the prevalence of respiratory infections in Ghana was
161 23.0%. Considering this prevalence, the sample size was pre-determined to be 272 [$n = Z^2 \frac{p \cdot q}{e^2}$
162 , $z = 1.9$, $p = 0.23$, $q = 0.77$, $e = 0.05$]. A convenience sampling method was used throughout
163 the study and patient recruitment was not done in parallel in each hospital. The general
164 demographics, including age, sex, and maternal education, were recorded using a standardised
165 questionnaire. Clinical data were extracted from the paediatrician’s folder. Clinical data
166 included symptoms (cough, runny nose, headache, difficulty breathing, etc.) and diagnosis
167 (URTI, bronchiolitis, pneumonia). Overall, 303 oropharyngeal swabs were collected with
168 flocked swabs (Copan Group, Brescia, Italy) and inserted into 1.5mL Eppendorf tubes
169 (Eppendorf, Germany) containing 500µl of viral transport medium (BioTeke Corporation Co.,

170 Ltd, China). The tubes were labelled with corresponding facility-specific identification
171 numbers and transported on ice to the Kumasi Centre for Collaborative Research in Tropical
172 Medicine (KCCR) for laboratory analysis.

173

174 ***Laboratory Analysis***

175 Nucleic acid extraction was done using the RADI PREP Swab and Stool DNA/RNA KIT (KH
176 Medical Co., Ltd, Republic of Korea) according to the manufacturer's instructions. Samples
177 were eluted in a 70µl volume and SARS-CoV-2 viral RNA detection was performed using the
178 RADI COVID-19 Detection Kit (KH Medical Co., Ltd, Republic of Korea) following the
179 manufacturer's instructions. The Invitrogen SuperScript III One-step RT-PCR System was
180 used for the detection of Flu A, Flu B, RSV, PIV I-III, HRV and HMPV. For HAdV testing,
181 the Qiagen 10X PCR buffer with Taq polymerase was used. Viral nucleic acid detection was
182 done by real-time Polymerase Chain Reaction (PCR) using the LineGene 9600 Plus
183 thermocycler (FQD-96A, Bioer Technology, China). All samples with a threshold cycle (Ct)
184 above 40 were considered negative. Positive and negative controls were included in each PCR
185 run for validation.

186

187 ***Statistical Analysis***

188 Data collected were entered into Microsoft Excel 2021, cleaned and exported to R
189 programming language version 4.3.0 for analysis. Descriptive statistics were used to
190 summarize the distribution of various variables into tables. Risk factors that had a significance
191 level of $p \leq 0.05$ in the univariate binary logistic regression analysis were subjected to
192 multivariate binary logistic regression analysis. The results were expressed as the adjusted odds

193 ratio (AOR) and 95% CI. All statistical tests with p-values less than 0.05 were considered
194 statistically significant.

195

196 **Results**

197 *Patient characteristics*

198 From August 2022 to June 2023, a total of 303 children aged less than 5 years were recruited
199 in this study. A majority (54.4%) were males aged 13 to 36 months (40.3%), with a median
200 age of 19 months. The study participants presented with more than one symptom, with the most
201 predominant being cough (87.0%), rhinorrhoea (87.0%) and fever (72.0%). The least recorded
202 symptoms were headache (34.0%) and vomiting (25.0%). Table 1 shows the characteristics of
203 the study population.

204 **Table 1: Characteristics of the study population**

| Variable | Number of participants (%) |
|----------------------------|-----------------------------------|
| Age (months) | |
| <6 | 45 (14.8) |
| 6-12 | 61 (20.1) |
| 13-36 | 122(40.3) |
| 37-60 | 75(24.8) |
| Gender | |
| Male | 165 (54.4) |
| Female | 138 (45.6) |
| Caregiver Education | |
| No formal education | 57 (19.0) |
| JHS/Primary | 42 (14.0) |
| SHS/Secondary | 54 (18.0) |
| Tertiary | 104 (34.0) |
| Symptoms | |

| | |
|---------------------|------------|
| Fever | 219 (72.0) |
| Cough | 265 (87.0) |
| Headache | 102 (34.0) |
| Shortness of breath | 122 (40.0) |
| Poor feeding | 115 (38.0) |
| Vomiting | 76 (25.0) |
| Rhinorrhoea | 265 (87.0) |
| Loss of appetite | 117 (39.0) |

205

206 ***Prevalence of respiratory viruses***

207 Among the 303 samples tested, a respiratory virus was detected in 100 (33.0%) of the samples.

208 In Table 2, it is shown that out of the samples tested, 92 (30.4%) showed single viral detections,

209 while co-detections were observed in 8 samples (2.64%, 95% CI: 0.83-4.45). The most

210 prevalent virus was HMPV with 36 cases (12.0%, 95% CI: 8.2-15.5), followed by RSV with

211 27 cases (8.9%, 95% CI: 5.7-12.1), and then HAdV with 20 cases (6.6%, 95% CI: 3.8-9.4). No

212 PIV-I was detected.

213 **Table 2: Prevalence of respiratory viruses**

| Viral respiratory pathogen | Frequency | Prevalence (%) |
|-----------------------------------|------------------|-----------------------|
| SARS-CoV-2 | 3 | 1.0 |
| HAdV | 20 | 6.6 |
| HRV | 6 | 2.0 |
| PIV-I | 0 | 0 |
| PIV-II | 2 | 0.7 |
| PIV-III | 2 | 0.7 |
| FLU A | 5 | 1.7 |
| FLU B | 7 | 2.3 |
| HMPV | 36 | 12.0 |
| RSV | 27 | 8.9 |

214 The most predominant virus identified in cases of co-detection was HAdV (n=6, 75.0%). Table
215 3 shows that HMPV co-detection was identified in 4 (50.0%) samples. SARS-CoV-2, HRV,
216 Flu A, Flu B, PIV-II, PIV-III and RSV were each identified in single cases of co-detection.

217 **Table 3: Single and double virus detections made during the study period**

| Virus | Number of samples (%) | SARS-CoV-2 | HAdV | HRV | PIV-II | PIV-III | FLU A | FLU B | HMPV | RSV |
|-------------------------|------------------------------|-------------------|-------------|------------|---------------|----------------|--------------|--------------|-------------|------------|
| SARS-CoV-2 | | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HAdV | | - | 14 | 0 | 0 | 0 | 1 | 1 | 3 | 1 |
| HRV | | - | - | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| PIV-II | | - | - | - | 1 | 1 | 0 | 0 | 0 | 0 |
| PIV-III | | - | - | - | - | 1 | 0 | 0 | 0 | 0 |
| FLU A | | - | - | - | - | - | 4 | 0 | 0 | 0 |
| FLU B | | - | - | - | - | - | - | 6 | 1 | 0 |
| HMPV | | - | - | - | - | - | - | - | 32 | 0 |
| RSV | | - | - | - | - | - | - | - | - | 26 |
| SINGLE DETECTION | 92 (92.0) | 2 | 14 | 6 | 1 | 1 | 4 | 6 | 32 | 26 |
| DOUBLE DETECTION | 8 (8.0) | 1 | 6 | 0 | 1 | 1 | 1 | 1 | 4 | 1 |
| TOTAL | 100 (100.0) | 3 | 20 | 6 | 2 | 2 | 5 | 7 | 36 | 27 |

219 ***Risk factors associated with respiratory viral detection***

220 The risk factor analysis was limited to HMPV, RSV, and HAdV due to the low prevalence of
221 other respiratory viruses. According to the multivariate binary logistic regression analysis of
222 the risk factors, children younger than 6 months (AOR: 4.81, 95% CI: 1.20-24.60) had higher
223 odds of RSV detection when compared to children aged 37 to 60 months. It is evident from
224 Table 4 that children with caregivers who had completed tertiary education (AOR: 6.91, 95%
225 CI: 1.71-47.30) were more likely to test positive for HMPV compared to those with caregivers
226 who had no formal education. The clinical risk factors evaluation in Table 5 showed that
227 children presenting with headache (AOR: 3.95, 95% CI: 1.35-12.60) had higher odds of testing
228 positive for HAdV compared to children without headache. In addition, children who presented
229 with shortness of breath (AOR: 0.33, 95% CI: 0.13-1.02) had lower odds of testing positive for
230 HMPV compared to children without shortness of breath.

231 **Table 4: Risk factors associated with respiratory viruses in the study population**

| Variable | OR (95% CI) | | | | | | AOR (95% CI) | | | | | |
|------------------|--------------|--------------|-------------|---------|-------------|---------|--------------|--------------|-------------|---------|-------------|---------|
| | RSV | p-value | HMPV | p-value | AdV | p-value | RSV | p-value | HMPV | p-value | AdV | p-value |
| Age group | | | | | | | | | | | | |
| 37-60 | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| <6 | 6.00 | 0.010 | 0.60 | 0.500 | 0.53 | 0.500 | 4.81 | 0.036 | 0.79 | 0.700 | 0.55 | 0.500 |
| | (1.68-28.30) | | (0.13-2.20) | | (0.08-2.44) | | (1.20-24.60) | | (0.16-3.11) | | (0.07-2.71) | |
| 6-12 | 2.14 | 0.300 | 0.91 | 0.900 | 0.59 | 0.500 | 2.21 | 0.300 | 0.96 | 0.900 | 0.60 | 0.500 |
| | (0.50-10.80) | | (0.29-2.78) | | (0.12-2.36) | | (0.48-11.90) | | (0.29-3.06) | | (0.12-2.48) | |
| 13-36 | 2.14 | 0.300 | 1.54 | 0.300 | 0.92 | 0.900 | 2.27 | 0.200 | 1.39 | 0.500 | 0.91 | 0.900 |
| | (0.63-9.8) | | (0.66-3.93) | | (0.32-2.84) | | (0.64-10.70) | | (0.57-3.62) | | (0.31-2.86) | |
| Gender | | | | | | | | | | | | |
| Female | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| Male | 0.46 | 0.062 | 0.82 | 0.600 | 0.83 | 0.700 | 0.46 | 0.069 | 0.89 | 0.800 | 0.83 | 0.700 |
| | (0.20-1.02) | | (0.40-1.65) | | (0.33-2.07) | | (0.19-1.05) | | (0.41-1.96) | | (0.31-2.18) | |

| Caregiver | | | | | | | | | | | | |
|------------------|-------------|-------|--------------|--------------|-------------|-------|-----|--|--------------|--------------|-------------|-------|
| Education | | | | | | | | | | | | |
| No education | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| JHS/Primary | 0.44 | 0.200 | 0.67 | 0.700 | 1.38 | 0.700 | - | | 0.90 | 0.900 | 1.00 | 0.900 |
| | (0.11-1.40) | | (0.03-7.23) | | (0.25-7.83) | | | | (0.04-10.50) | | (0.15-6.48) | |
| SHS | - | | 7.03 | 0.014 | 1.06 | 0.900 | - | | 6.91 | 0.020 | 0.98 | 0.900 |
| /Secondary | | | (1.77-47.00) | | (0.19-5.95) | | | | (1.60-48.50) | | (0.16-5.94) | |
| Tertiary | 0.21 | | 6.55 | 0.014 | 1.91 | 0.300 | - | | 6.91 | 0.017 | 2.27 | 0.300 |
| | (0.06-0.62) | | (1.81-42.00) | | (0.56-8.81) | | | | (1.71-47.30) | | (0.59) | |

233 **Table 5: Clinical symptoms associated with respiratory viruses in the study population**

| Variable | OR (95% CI) | | | | | AOR (95% CI) | | | | | | |
|-------------------------|---------------------|---------|---------------------|---------|---------------------|--------------|---------------------|---------|---------------------|---------|---------------------|--------------|
| | RSV | p-value | HMPV | p-value | AdV | p-value | RSV | p-value | HMPV | p-value | AdV | p-value |
| Clinical Symptom | | | | | | | | | | | | |
| Fever | | | | | | | | | | | | |
| No | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| Yes | 1.38 (0.57-3.87) | 0.500 | 0.86 (0.40-1.65) | 0.700 | 1.16 (0.43-3.67) | 0.800 | 1.68 (0.64-5.08) | 0.300 | 0.88 (0.37-2.15) | 0.800 | 0.83 (0.26-2.88) | 0.700 |
| Cough | | | | | | | | | | | | |
| No | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| Yes | - | | 2.65 (0.76-16.8) | 0.200 | 0.55 (0.19-1.99) | 0.300 | - | | 2.77 (0.65-20.5) | 0.200 | 0.48 (0.15-1.86) | 0.200 |
| Headache | | | | | | | | | | | | |
| No | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| Yes | 0.54 (0.19-1.30) | 0.200 | 0.85 (0.39-1.77) | 0.700 | 3.22 (1.29-8.47) | 0.014 | 0.75 (0.25-2.01) | 0.600 | 1.12 (0.46-2.65) | 0.800 | 3.95 (1.35-12.6) | 0.015 |

| | | | | | | | | | | | | |
|----------------------------|--------------|-------|-------------|--------------|-------------|-------|--------------|-------|-------------|--------------|-------------|-------|
| Shortness of breath | | | | | | | | | | | | |
| No | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| Yes | 1.02 | 0.900 | 0.38 | 0.022 | 0.79 | 0.600 | 1.07 | 0.900 | 0.33 | 0.014 | 0.76 | 0.600 |
| | (0.45-2.27) | | (0.16-0.84) | | (0.29-1.98) | | (0.45-2.50) | | (0.13-1.02) | | (0.26-2.06) | |
| Rhinorrhoea | | | | | | | | | | | | |
| No | Ref | | Ref | | Ref | | Ref | 0.400 | Ref | | Ref | |
| Yes | 1.87 | 0.400 | 0.44 | 0.067 | - | | 1.98 | | 0.36 | 0.055 | - | |
| | (0.53-12.00) | | (0.19-1.12) | | | | (0.54-12.90) | | (0.13-0.77) | | | |
| Poor feeding | | | | | | | | | | | | |
| No | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| Yes | 0.80 | 0.600 | 0.43 | 0.043 | 1.37 | 0.500 | 0.81 | 0.600 | 0.39 | 0.052 | 1.07 | 0.900 |
| | (0.33-1.81) | | (0.18-0.93) | | (0.53-3.41) | | (0.32-1.94) | | (0.15-0.97) | | (0.38-2.94) | |
| Vomiting | | | | | | | | | | | | |
| No | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| Yes | 0.84 | 0.700 | 0.34 | 0.048 | 2.11 | 0.120 | 0.81 | 0.700 | 0.55 | 0.300 | 2.13 | 0.140 |
| | (0.30-2.05) | | (0.10-0.89) | | (0.80-5.31) | | (0.27-2.11) | | (0.15-1.64) | | (0.75-5.84) | |

235 Discussion

236 The present study emphasized the prevalence of various respiratory viruses including RSV, Flu
237 A, Flu B, HPIV I, II, III, HAdV, SARS-CoV-2, HRV, and HMPV among children exhibiting
238 respiratory symptoms and signs. The overall prevalence recorded among the study participants
239 was 33.0% (95% CI: 27.70-38.30). Previous studies from Ghana, prior to the COVID-19
240 pandemic, have reported varying estimates of prevalence of respiratory viruses from 12.5% to
241 73.0% among the paediatric population [1, 17, 18,19]. From those studies, relatively higher
242 viral prevalence has been observed among hospitalized cases with more severe symptoms than
243 cases recruited in the outpatient department (OPD), as was done in the present study [1, 17,
244 18,19]. In other parts of Africa, higher viral prevalence was reported in Burkina Faso (85.0%),
245 Kenya (68.0%) and Cameroon (65.0%) [20–22]. Generally, variations in prevalence of
246 respiratory viruses can be attributed to a number of reasons, including the panel of viral agents
247 tested, the duration of the study, climatic conditions and enrolment criteria [23]. The
248 recruitment of outpatients in the present study could account for the relatively lower viral
249 prevalence in comparison with previously published studies that recruited hospitalized patients.
250 HMPV was the most predominant virus, identified in 12.0% of the recruited participants.
251 Approximately 90.0% of the HMPV cases were detected in one site during a three-week period,
252 leading to a higher prevalence compared to previous reports in Ghana [1,18,19]. This increase
253 may have been caused by an undetected HMPV outbreak, driven by nosocomial infections
254 which is an existing significant public health concern, especially among paediatric patients
255 [24]. The absence of viral testing in Ghanaian healthcare facilities further complicates the
256 detection of such outbreaks. Recent studies since the decline of SARS-CoV-2 cases have also
257 reported high prevalence of HMPV in Myanmar (13.0%), USA (12.6%) and Nepal (13.3%)
258 [5,25,26]. RSV, which has been implicated as a major cause of ARI in children, was identified
259 in 8.9% of the study population. The aggressive implementation of non-pharmaceutical

260 interventions (NPIs) during the COVID-19 pandemic led to a significant decline in RSV cases
261 among young children globally, as reported in South Africa (4.1%), the United Kingdom
262 (0.1%) and Canada (0.05%) [12,13,27]. However, with the gradual relaxation of NPIs,
263 countries like Egypt (20.9%) and China (21.7%) witnessed a resurgence in RSV cases,
264 particularly among young children [28,29]. The finding from this study emphasizes the
265 importance of active surveillance in enhancing the management of RSV-related respiratory
266 infections in young children. The prevalence of HAdV (6.6%), HRV (2.0%), flu A (1.7%), and
267 Flu B (2.3%) in the present study was lower than previous studies conducted pre-COVID-19
268 pandemic among Ghanaian children [9,17–19]. Apart from Influenza, which is under routine
269 surveillance in Ghana, respiratory viruses are not routinely sought for in Ghanaian healthcare
270 facilities [(9)]. The relatively lower prevalence still, however, highlights the circulation of these
271 viruses and a major implication of the failure to detect them may cause an increase in
272 antimicrobial resistance as antibiotics are often prescribed to treat apparent respiratory
273 infections [30]. Young children have been reported to be less often infected by SARS-CoV-2
274 when compared to adults [31], and unsurprisingly, the 1.0% prevalence from our study was
275 similarly as low as reported among children (0.4%) during the peak of the COVID-19 pandemic
276 in Ghana [32]. Comparisons with studies from other parts of the world revealed that regardless
277 of the clinical profile, SARS-CoV-2 prevalence remains low among children [33–35]. HPIV-
278 II and HPIV-III were both detected in 0.7% of the study group with no detection (0%) for
279 HPIV-I. This was lower than previous reports in Ghana [36, 17,19], and other African countries
280 like Cameroon and Niger [22,23]. It is possible there may have been low viral activity of HPIV
281 since there was no year-round sampling. Generally, the limited diagnostic capacity of
282 healthcare facilities to detect respiratory viruses increases the risk of infected children
283 unknowingly transmitting these viruses to others in daycare, schools and households.
284 Consequently, this adds more burden to the constrained healthcare system in Ghana.

285 HMPV and HAdV accounted for 3 (37.5%) of the 8 co-detections observed in this study. Single
286 cases of co-detection were observed for the HAdV and RSV, HAdV and SARS-CoV-2, HAdV
287 and flu A, HMPV and flu B, and PIV-II and PIV-III. Literature on viral co-detection in
288 respiratory illness among children shows conflicting results. Some studies [37,38] suggest
289 worse outcomes and longer hospital stays, whereas others [39,40] found no association
290 between viral co-detection and illness severity. Our study however, did not determine the
291 association between viral co-detection and its impact on health, as only outpatients were
292 recruited.

293 We identified age as a risk factor for RSV detection in our study. Children aged younger than
294 6 months (AOR: 4.81, 95% CI: 1.20-24.60) had higher odds of testing positive for RSV when
295 compared to those aged from 37 to 60 months. This is consistent with other studies that
296 identified a higher risk of RSV infection among children less than 6 months than other age
297 groups [41,42]. Children younger than six months are biologically more vulnerable to ARIs
298 due to the ongoing development of their immune system and lungs, leaving them with
299 insufficient immunity when exposed to infections [43].

300 Our study identified secondary and tertiary level of caregiver education as risk factors for
301 HMPV detection. Children whose caregivers had attained secondary (AOR: 6.91, 95% CI:
302 1.60-48.50) and tertiary (AOR: 6.91, 95% CI: 1.71-47.30) education had higher odds of HMPV
303 detection when compared to those with caregivers of no formal education. This was in contrast
304 to findings by Ujunwa in Nigeria and Tazinya in Cameroon, who suggested that no formal
305 education among caregivers led to poor hygienic practices in homes which increased the risk
306 of respiratory viral detection among children [44,45]. A possible explanation for our finding
307 could be that caregivers with higher education may enrol children in crowded daycare settings
308 and kindergartens, potentially increasing the risk of respiratory virus transmission, such as
309 HMPV. We identified headache as a clinical risk factor for HAdV detection in our study.

310 Children with headaches (AOR: 3.95, 95% CI: 1.35-12.60) had higher odds of testing positive
311 for HAdV than those without headaches. This aligns with a study in Senegal linking HAdV
312 detection to headaches in children with respiratory illness [46]. Headaches in infants have been
313 associated with adenoviral pharyngitis, and common cold symptoms induced by HAdV, such
314 as sneezing and sinus inflammation, which can contribute to headache sensations [47,48].
315 Children with shortness of breath (AOR: 0.33, 95% CI: 0.13-1.02) in our study had lower odds
316 of testing positive for HMPV, contrary to previous studies associating dyspnoea with HMPV
317 infection [49–51]. The discrepancy might be due to potential non-viral causes, like
318 *Streptococcus pneumoniae* or *Haemophilus influenzae*, which were not assessed in this study
319 but are known to cause bacterial pneumonia with similar symptoms [52].

320

321 **Conclusion**

322 The results of our study indicate that HMPV, the most common respiratory virus, may have a
323 more significant impact on the cause of respiratory illness in Ghanaian children than previously
324 believed. The increased scientific and public awareness of the burden of respiratory infections
325 by the COVID-19 pandemic provides a good opportunity to make advances towards reducing
326 the spread of common respiratory viruses. Further studies should be conducted in other
327 geographical locations in the country to elucidate the viral prevalence patterns and provide a
328 comprehensive overview of the respiratory virome in the Ghanaian paediatric population.

329

330 **Acknowledgements**

331 We want to acknowledge all participants and their families who agreed to participate in the
332 study. Additionally, we also acknowledge Annie Sarpong Animwaa and Abigail Achiaa Akoto
333 for their help in participant recruitment. There was no specific funding for this study.

334 **Supporting information**

335 S1_Checklist: Clinical Studies Checklist

336 S2_Checklist: STROBE checklist

337 **S3 data.** Dataset for study: DOI 10.17605/OSF.IO/QW2HU

338

339

340

341 **References**

- 342 1. Kafintu-Kwashie AA, Nii-Trebi NI, Obodai E, Neizer M, Adiku TK, Odoom JK.
343 Molecular epidemiological surveillance of viral agents of acute lower respiratory tract
344 infections in children in Accra, Ghana. *BMC Pediatr* [Internet]. 2022;22(1):1–9.
345 Available from: <https://doi.org/10.1186/s12887-022-03419-7>
- 346 2. Apanga PA, Kumbeni MT. Factors associated with diarrhoea and acute respiratory
347 infection in children under-5 years old in Ghana: an analysis of a national cross-sectional
348 survey. *BMC Pediatr*. 2021;21(1):1–8.
- 349 3. Abbey M, Afagbedzi SK, Afriyie-Mensah J, Antwi-Agyei D, Atengble K, Badoe E, et
350 al. Pneumonia in Ghana-a need to raise the profile. *Int Health*. 2018;10(1):4–7.
- 351 4. Falkenstein-Hagander K, Mansson AS, Redmo J, Nilsson Wimar P, Widell A. Viral
352 aetiology and clinical outcomes in hospitalised infants presenting with respiratory
353 distress. *Acta Paediatr Int J Paediatr*. 2014;103(6):625–9.
- 354 5. Lamichhane J, Upreti M, Nepal K, Upadhyay BP, Maharjan U, Shrestha RK, et al.
355 Burden of human metapneumovirus infections among children with acute respiratory
356 tract infections attending a Tertiary Care Hospital, Kathmandu. *BMC Pediatr* [Internet].

- 357 2023 Dec 1 [cited 2023 Nov 12];23(1). Available from: </pmc/articles/PMC10405573/>
- 358 6. Shafik CF, Mohareb EW, Yassin AS, Amin MA, El Kholy A, El-Karakasy H, et al. Viral
359 etiologies of lower respiratory tract infections among Egyptian children under five years
360 of age. *BMC Infect Dis* [Internet]. 2012 Dec 13 [cited 2023 Sep 15];12(1):1–8.
361 Available from: [https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-](https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-12-350)
362 [12-350](https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-12-350)
- 363 7. O’Callaghan-Gordo C, Díez-Padrisa N, Abacassamo F, Pérez-Breña P, Casas I, Alonso
364 PL, et al. Viral acute respiratory infections among infants visited in a rural hospital of
365 southern Mozambique. *Trop Med Int Heal* [Internet]. 2011 Sep 1 [cited 2023 Sep
366 25];16(9):1054–60. Available from:
367 <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-3156.2011.02811.x>
- 368 8. Jroundi I, Mahraoui C, Benmessaoud R, Moraleda C, Tligui H, Seffar M, et al. A
369 comparison of human metapneumovirus and respiratory syncytial virus WHO-defined
370 severe pneumonia in Moroccan children. *Epidemiol Infect* [Internet]. 2016 Feb 1 [cited
371 2024 May 6];144(3):516–26. Available from:
372 [https://www.cambridge.org/core/journals/epidemiology-and-](https://www.cambridge.org/core/journals/epidemiology-and-infection/article/comparison-of-human-metapneumovirus-and-respiratory-syncytial-virus-whodefined-severe-pneumonia-in-moroccan-children/84C1BCBF6A98FFDA3BB9CFAE27C63222)
373 [infection/article/comparison-of-human-metapneumovirus-and-respiratory-syncytial-](https://www.cambridge.org/core/journals/epidemiology-and-infection/article/comparison-of-human-metapneumovirus-and-respiratory-syncytial-virus-whodefined-severe-pneumonia-in-moroccan-children/84C1BCBF6A98FFDA3BB9CFAE27C63222)
374 [virus-whodefined-severe-pneumonia-in-moroccan-](https://www.cambridge.org/core/journals/epidemiology-and-infection/article/comparison-of-human-metapneumovirus-and-respiratory-syncytial-virus-whodefined-severe-pneumonia-in-moroccan-children/84C1BCBF6A98FFDA3BB9CFAE27C63222)
375 [children/84C1BCBF6A98FFDA3BB9CFAE27C63222](https://www.cambridge.org/core/journals/epidemiology-and-infection/article/comparison-of-human-metapneumovirus-and-respiratory-syncytial-virus-whodefined-severe-pneumonia-in-moroccan-children/84C1BCBF6A98FFDA3BB9CFAE27C63222)
- 376 9. Hogan B, Ammer L, Zimmermann M, Binger T, Krumkamp R, Sarpong N, et al. Burden
377 of influenza among hospitalized febrile children in Ghana. *Influenza Other Respi*
378 *Viruses*. 2017;11(6):497–501.
- 379 10. Afulani PA, Gyamerah AO, Nutor JJ, Laar A, Aborigo RA, Malechi H, et al. Inadequate
380 preparedness for response to COVID-19 is associated with stress and burnout among

- 381 healthcare workers in Ghana. PLoS One [Internet]. 2021 Apr 1 [cited 2023 Mar
382 29];16(4):e0250294. Available from:
383 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0250294>
- 384 11. Rehman SU, Rehman SU, Yoo HH. COVID-19 challenges and its therapeutics. Biomed
385 Pharmacother [Internet]. 2021 Oct 1 [cited 2024 May 6];142:112015. Available from:
386 </pmc/articles/PMC8339548/>
- 387 12. Tempia S, Walaza S, Bhiman JN, McMorrow ML, Moyes J, Mkhencele T, et al. Decline
388 of influenza and respiratory syncytial virus detection in facility-based surveillance
389 during the COVID-19 pandemic, South Africa, January to October 2020.
390 Eurosurveillance [Internet]. 2021 Jul 7 [cited 2023 Nov 13];26(29). Available from:
391 </pmc/articles/PMC8299743/>
- 392 13. Groves HE, Piché-Renaud PP, Peci A, Farrar DS, Buckrell S, Bancej C, et al. The impact
393 of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal
394 respiratory virus circulation in Canada: A population-based study. Lancet Reg Heal -
395 Am [Internet]. 2021 Sep 1 [cited 2023 Mar 19];1:15. Available from:
396 </pmc/articles/PMC8285668/>
- 397 14. Kandeel A, Fahim M, Deghedy O, Roshdy WH, Khalifa MK, Shesheny R El, et al.
398 Resurgence of influenza and respiratory syncytial virus in Egypt following two years of
399 decline during the COVID-19 pandemic: outpatient clinic survey of infants and children,
400 October 2022. BMC Public Health [Internet]. 2023 Dec 1 [cited 2023 Nov 13];23(1):1–
401 9. Available from:
402 <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-023-15880-9>
- 403 15. World Health Organization. Acute respiratory infections in children: Case management
404 in small hospitals in developing countries. 1990.

- 405 16. Obodai E, Odoom JK, Adiku T, Goka B, Wolff T, Biere B, et al. Erratum: The
406 significance of human respiratory syncytial virus (HRSV) in children from Ghana with
407 acute lower respiratory tract infection: A molecular epidemiological analysis, 2006 and
408 2013-2014 (PLoS ONE (2019) 13:9 (e0203788)Doi: 10.1371/journal.pone.0. PLoS
409 One. 2019;14(8):1–17.
- 410 17. Annan A, Ebach F, Corman VM, Krumkamp R, Adu-Sarkodie Y, Eis-Hübinger AM, et
411 al. Similar virus spectra and seasonality in paediatric patients with acute respiratory
412 disease, Ghana and Germany. *Clin Microbiol Infect* [Internet]. 2016 Apr 1 [cited 2023
413 May 17];22(4):340. Available from: </pmc/articles/PMC7172147/>
- 414 18. Krumkamp R, Kohsar M, Nolte K, Hogan B, Eibach D, Jaeger A, et al. Pathogens
415 associated with hospitalization due to acute lower respiratory tract infections in children
416 in rural Ghana: a case-control study. *Sci Rep* [Internet]. 2023;13(1):2443. Available
417 from: <https://doi.org/10.1038/s41598-023-29410-5>
- 418 19. Obodai E. Molecular Epidemiology of Respiratory Viruses associated with Acute Lower
419 Respiratory Tract Infections in Children from Ghana. 2016; Available from:
420 <https://refubium.fu-berlin.de/handle/fub188/2268>
- 421 20. Ouédraogo S, Traoré B, Bi ZABN, Yonli FT, Kima D, Bonané P, et al. Viral etiology
422 of respiratory tract infections in children at the pediatric hospital in Ouagadougou
423 (Burkina Faso). *PLoS One*. 2014 Oct 31;9(10).
- 424 21. Feikin DR, Njenga MK, Bigogo G, Aura B, Aol G, Audi A, et al. Viral and bacterial
425 causes of severe acute respiratory illness among children aged less than 5 years in a high
426 malaria prevalence area of Western Kenya, 2007-2010. *Pediatr Infect Dis J* [Internet].
427 2013 Jan [cited 2023 Sep 7];32(1). Available from:
428 https://journals.lww.com/pidj/fulltext/2013/01000/viral_and_bacterial_causes_of_seve

429 re_acute.10.aspx

430 22. Kenmoe S, Tchendjou P, Vernet MA, Moyo-Tetang S, Mossus T, Njankouo-Ripa M, et
431 al. Viral etiology of severe acute respiratory infections in hospitalized children in
432 Cameroon, 2011–2013. *Influenza Other Respi Viruses* [Internet]. 2016 Sep 1 [cited 2023
433 Sep 8];10(5):386. Available from: [/pmc/articles/PMC4947949/](#)

434 23. Lagare A, Maïnassara HB, Issaka B, Sidiki A, Tempia S. Viral and bacterial etiology of
435 severe acute respiratory illness among children < 5 years of age without influenza in
436 Niger. *BMC Infect Dis* [Internet]. 2015 Nov 14 [cited 2023 Sep 8];15(1):1–7. Available
437 from: <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-1251-y>

438 24. Chow EJ, Mermel LA. Hospital-Acquired Respiratory Viral Infections: Incidence,
439 Morbidity, and Mortality in Pediatric and Adult Patients. *Open Forum Infect Dis*
440 [Internet]. 2017 Jan 1 [cited 2023 Sep 15];4(1). Available from:
441 [/pmc/articles/PMC5414085/](#)

442 25. Kamata K, Thein KN, Di Ja L, Win NC, Win SMK, Suzuki Y, et al. Clinical
443 manifestations and outcome of viral acute lower respiratory infection in hospitalised
444 children in Myanmar. *BMC Infect Dis* [Internet]. 2022 Dec 1 [cited 2023 Sep
445 28];22(1):1–17. Available from:
446 <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07342-1>

447 26. Howard LM, Edwards KM, Zhu Y, Grijalva CG, Self WH, Jain S, et al. Clinical Features
448 of Human Metapneumovirus-Associated Community-acquired Pneumonia
449 Hospitalizations. *Clin Infect Dis An Off Publ Infect Dis Soc Am* [Internet]. 2021 Jan 1
450 [cited 2023 Oct 5];72(1):108. Available from: [/pmc/articles/PMC7823075/](#)

451 27. Bardsley M, Morbey RA, Hughes HE, Beck CR, Watson CH, Zhao H, et al.
452 Epidemiology of respiratory syncytial virus in children younger than 5 years in England

- 453 during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic
454 surveillance: a retrospective observational study. *Lancet Infect Dis* [Internet]. 2023 Jan
455 1 [cited 2023 Nov 13];23(1):56. Available from: [/pmc/articles/PMC9762748/](#)
- 456 28. Abu-Raya B, Viñeta Paramo M, Reicherz F, Lavoie PM. Why has the epidemiology of
457 RSV changed during the COVID-19 pandemic? *eClinicalMedicine* [Internet]. 2023 Jul
458 1 [cited 2023 Nov 13];61. Available from:
459 <http://www.thelancet.com/article/S2589537023002663/fulltext>
- 460 29. Chuang YC, Lin KP, Wang LA, Yeh TK, Liu PY. The Impact of the COVID-19
461 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review. *Infect Drug*
462 *Resist* [Internet]. 2023 [cited 2023 Nov 13];16:661. Available from:
463 [/pmc/articles/PMC9897071/](#)
- 464 30. Labi AK, Obeng-Nkrumah N, Nartey ET, Bjerrum S, Adu-Aryee NA, Ofori-Adjei YA,
465 et al. Antibiotic use in a tertiary healthcare facility in Ghana: A point prevalence survey.
466 *Antimicrob Resist Infect Control* [Internet]. 2018 Jan 26 [cited 2023 Nov 12];7(1):1–9.
467 Available from: [https://aricjournal.biomedcentral.com/articles/10.1186/s13756-018-](https://aricjournal.biomedcentral.com/articles/10.1186/s13756-018-0299-z)
468 [0299-z](https://aricjournal.biomedcentral.com/articles/10.1186/s13756-018-0299-z)
- 469 31. Howard-Jones AR, Bowen AC, Danchin M, Koirala A, Sharma K, Yeoh DK, et al.
470 COVID-19 in children: I. Epidemiology, prevention and indirect impacts. *J Paediatr*
471 *Child Health* [Internet]. 2022 Jan 1 [cited 2023 Sep 26];58(1):39. Available from:
472 [/pmc/articles/PMC8662210/](#)
- 473 32. Owusu M, Sylverken AA, Ankrah ST, El-Duah P, Ayisi-Boateng NK, Yeboah R, et al.
474 Epidemiological profile of SARS-CoV-2 among selected regions in Ghana: A cross-
475 sectional retrospective study. *PLoS One*. 2020;15(12 December):1–15.
- 476 33. Hua W, Xiaofeng L, Zhenqiang B, Jun R, Ban W, Liming L. [The epidemiological

- 477 characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in
478 China]. *Zhonghua Liu Xing Bing Xue Za Zhi* [Internet]. 2020 Feb 1 [cited 2023 Sep
479 26];41(2):297–300. Available from: <https://pubmed.ncbi.nlm.nih.gov/32064853/>
- 480 34. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
481 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases
482 From the Chinese Center for Disease Control and Prevention. *JAMA* [Internet]. 2020
483 Apr 7 [cited 2023 Jun 11];323(13):1239–42. Available from:
484 <https://jamanetwork.com/journals/jama/fullarticle/2762130>
- 485 35. Eskander E, Jung C, Levy C, Béchet S, Blot N, Gorde S, et al. Assessment of SARS-
486 CoV-2 testing in children during a low prevalence period (VIGIL study 1). *Infect Dis
487 Now* [Internet]. 2021 Sep 1 [cited 2023 Sep 26];51(6):552. Available from:
488 </pmc/articles/PMC8276575/>
- 489 36. Kwofie TB, Anane YA, Nkrumah B, Annan A, Nguah SB, Owusu M. Respiratory
490 viruses in children hospitalized for acute lower respiratory tract infection in Ghana. *Virology
491 J* [Internet]. 2012 Apr 10 [cited 2023 May 17];9(1):1–8. Available from:
492 <https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-9-78>
- 493 37. Xie L, Zhang B, Xiao N, Zhang F, Zhao X, Liu Q, et al. Epidemiology of human
494 adenovirus infection in children hospitalized with lower respiratory tract infections in
495 Hunan, China. *J Med Virol* [Internet]. 2019 Mar 1 [cited 2023 Jun 10];91(3):392.
496 Available from: </pmc/articles/PMC7159165/>
- 497 38. Arnold FW, Fuqua JL. Viral respiratory infections: A cause of community-acquired
498 pneumonia or a predisposing factor? *Curr Opin Pulm Med* [Internet]. 2020 May 1 [cited
499 2023 May 24];26(3):208–14. Available from: [https://journals.lww.com/co-
500 pulmonarymedicine/Fulltext/2020/05000/Viral_respiratory_infections__a_cause_of.5](https://journals.lww.com/co-pulmonarymedicine/Fulltext/2020/05000/Viral_respiratory_infections__a_cause_of.5)

- 501 aspx
- 502 39. Scotta MC, Chakr VCBG, de Moura A, Becker RG, de Souza APD, Jones MH, et al.
503 Respiratory viral coinfection and disease severity in children: A systematic review and
504 meta-analysis. *J Clin Virol* [Internet]. 2016 Jul 1 [cited 2023 May 24];80:45. Available
505 from: [/pmc/articles/PMC7185664/](https://pubmed.ncbi.nlm.nih.gov/3185664/)
- 506 40. Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, et al. SARS-
507 CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses.
508 *Lancet* (London, England) [Internet]. 2022 Apr 16 [cited 2023 May
509 24];399(10334):1463. Available from: [/pmc/articles/PMC8956294/](https://pubmed.ncbi.nlm.nih.gov/38956294/)
- 510 41. Hasan MM, Saha KK, Yunus RM, Alam K. Prevalence of acute respiratory infections
511 among children in India: Regional inequalities and risk factors. *Matern Child Health J*
512 [Internet]. 2022 Jul 1 [cited 2024 May 6];26(7):1594. Available from:
513 [/pmc/articles/PMC9174316/](https://pubmed.ncbi.nlm.nih.gov/39174316/)
- 514 42. Sun YP, Qiang HS, Lei SY, Zheng XY, Zhang HX, Su YY, et al. Epidemiological
515 Features, Risk Factors, and Disease Burden of Respiratory Viruses among Hospitalized
516 Children with Acute Respiratory Tract Infections in Xiamen, China. *Jpn J Infect Dis*
517 [Internet]. 2022 [cited 2024 May 6];75(6):537–42. Available from:
518 <https://pubmed.ncbi.nlm.nih.gov/35768274/>
- 519 43. Schraufnagel DE, Balmes JR, Cowl CT, De Matteis S, Jung SH, Mortimer K, et al. Air
520 Pollution and Noncommunicable Diseases: A Review by the Forum of International
521 Respiratory Societies’ Environmental Committee, Part 2: Air Pollution and Organ
522 Systems. *Chest* [Internet]. 2019 Feb 1 [cited 2024 May 6];155(2):417. Available from:
523 [/pmc/articles/PMC6904854/](https://pubmed.ncbi.nlm.nih.gov/36904854/)
- 524 44. Ujunwa F, Ezeonu C. Risk Factors for Acute Respiratory Tract Infections in Under-five

- 525 Children in Enugu Southeast Nigeria. *Ann Med Health Sci Res* [Internet]. 2014 [cited
526 2023 May 27];4(1):95. Available from: [/pmc/articles/PMC3952306/](https://pubmed.ncbi.nlm.nih.gov/3952306/)
- 527 45. Tazinya AA, Halle-Ekane GE, Mbuagbaw LT, Abanda M, Atashili J, Obama MT. Risk
528 factors for acute respiratory infections in children under five years attending the
529 Bamenda Regional Hospital in Cameroon. *BMC Pulm Med* [Internet]. 2018 Jan 16
530 [cited 2023 Oct 4];18(1). Available from: [/pmc/articles/PMC5771025/](https://pubmed.ncbi.nlm.nih.gov/35771025/)
- 531 46. Niang MN, Diop NS, Fall A, Kiori DE, Sarr FD, Sy S, et al. Respiratory viruses in
532 patients with influenza-like illness in Senegal: Focus on human respiratory
533 adenoviruses. *PLoS One* [Internet]. 2017 Mar 1 [cited 2023 Oct 5];12(3). Available
534 from: [/pmc/articles/PMC5362214/](https://pubmed.ncbi.nlm.nih.gov/25362214/)
- 535 47. Shieh WJ. Human adenovirus infections in pediatric population - An update on clinico-
536 pathologic correlation. *Biomed J* [Internet]. 2022 Feb 1 [cited 2023 Oct 5];45(1):38.
537 Available from: [/pmc/articles/PMC9133246/](https://pubmed.ncbi.nlm.nih.gov/4133246/)
- 538 48. Kirkpatrick GL. THE COMMON COLD. *Prim Care* [Internet]. 1996 Dec 12 [cited 2023
539 Oct 5];23(4):657. Available from: [/pmc/articles/PMC7125839/](https://pubmed.ncbi.nlm.nih.gov/7125839/)
- 540 49. Williams J V., Edwards KM, Weinberg GA, Griffin MR, Hall CB, Zhu Y, et al.
541 Population-Based Incidence of Human Metapneumovirus Infection among Hospitalized
542 Children. *J Infect Dis* [Internet]. 2010 Jun 15 [cited 2023 Oct 5];201(12):1890–8.
543 Available from: [https://dx.doi.org/10.1086/652782](https://doi.org/10.1086/652782)
- 544 50. Howard LM, Edwards KM, Zhu Y, Griffin MR, Weinberg GA, Szilagyi PG, et al.
545 Clinical Features of Human Metapneumovirus Infection in Ambulatory Children Aged
546 5–13 Years. *J Pediatric Infect Dis Soc* [Internet]. 2018 [cited 2023 Oct 5];7(2):165.
547 Available from: [/pmc/articles/PMC5954304/](https://pubmed.ncbi.nlm.nih.gov/35954304/)

- 548 51. Noordeen F, Pitchai FNN, Kudagammana ST, Rafeek RAM. A mini outbreak of human
549 metapneumovirus infection with severe acute respiratory symptoms in a selected group
550 of children presented to a teaching hospital in Sri Lanka. *VirusDisease* [Internet]. 2019
551 Jun 1 [cited 2023 Oct 5];30(2):307–10. Available from:
552 <https://link.springer.com/article/10.1007/s13337-019-00522-9>
- 553 52. Nathan AM, Teh CSJ, Jabar KA, Teoh BT, Tangaperumal A, Westerhout C, et al.
554 Bacterial pneumonia and its associated factors in children from a developing country:
555 A prospective cohort study. *PLoS One* [Internet]. 2020 Feb 1 [cited 2023 Oct 5];15(2).
556 Available from: </pmc/articles/PMC7021284/>